Cargando…
Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
BACKGROUND: In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mosby
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807653/ https://www.ncbi.nlm.nih.gov/pubmed/24093845 http://dx.doi.org/10.1016/j.ahj.2013.07.011 |
_version_ | 1782288497248305152 |
---|---|
author | Berry, Colin Layland, Jamie Sood, Arvind Curzen, Nick P. Balachandran, Kanarath P. Das, Raj Junejo, Shahid Henderson, Robert A. Briggs, Andrew H. Ford, Ian Oldroyd, Keith G. |
author_facet | Berry, Colin Layland, Jamie Sood, Arvind Curzen, Nick P. Balachandran, Kanarath P. Das, Raj Junejo, Shahid Henderson, Robert A. Briggs, Andrew H. Ford, Ian Oldroyd, Keith G. |
author_sort | Berry, Colin |
collection | PubMed |
description | BACKGROUND: In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic, clinical, and health economic utility as compared with angiography-guided standard care. METHODS AND DESIGN: A prospective multicenter parallel-group 1:1 randomized controlled superiority trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will be disclosed to guide treatment in the FFR-guided group but not disclosed in the “angiography-guided” group. In the FFR-guided group, an FFR ≤0.80 will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as appropriate. The primary outcome is the between-group difference in the proportion of patients allocated to medical management only compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial infarction or heart failure, quality of life, and health care costs. The minimum and average follow-up periods for the primary analysis are 6 and 18 months, respectively. CONCLUSIONS: Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the influence of FFR disclosure on treatment decisions and health and economic outcomes. |
format | Online Article Text |
id | pubmed-3807653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Mosby |
record_format | MEDLINE/PubMed |
spelling | pubmed-38076532013-10-25 Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() Berry, Colin Layland, Jamie Sood, Arvind Curzen, Nick P. Balachandran, Kanarath P. Das, Raj Junejo, Shahid Henderson, Robert A. Briggs, Andrew H. Ford, Ian Oldroyd, Keith G. Am Heart J Trial Design BACKGROUND: In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic, clinical, and health economic utility as compared with angiography-guided standard care. METHODS AND DESIGN: A prospective multicenter parallel-group 1:1 randomized controlled superiority trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will be disclosed to guide treatment in the FFR-guided group but not disclosed in the “angiography-guided” group. In the FFR-guided group, an FFR ≤0.80 will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as appropriate. The primary outcome is the between-group difference in the proportion of patients allocated to medical management only compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial infarction or heart failure, quality of life, and health care costs. The minimum and average follow-up periods for the primary analysis are 6 and 18 months, respectively. CONCLUSIONS: Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the influence of FFR disclosure on treatment decisions and health and economic outcomes. Mosby 2013-10 /pmc/articles/PMC3807653/ /pubmed/24093845 http://dx.doi.org/10.1016/j.ahj.2013.07.011 Text en © 2013 The Authors https://creativecommons.org/licenses/by-nc-nd/3.0/ Open Access under CC BY-NC-ND 3.0 (https://creativecommons.org/licenses/by-nc-nd/3.0/) license |
spellingShingle | Trial Design Berry, Colin Layland, Jamie Sood, Arvind Curzen, Nick P. Balachandran, Kanarath P. Das, Raj Junejo, Shahid Henderson, Robert A. Briggs, Andrew H. Ford, Ian Oldroyd, Keith G. Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() |
title | Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() |
title_full | Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() |
title_fullStr | Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() |
title_full_unstemmed | Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() |
title_short | Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() |
title_sort | fractional flow reserve versus angiography in guiding management to optimize outcomes in non–st-elevation myocardial infarction (famous-nstemi): rationale and design of a randomized controlled clinical trial() |
topic | Trial Design |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807653/ https://www.ncbi.nlm.nih.gov/pubmed/24093845 http://dx.doi.org/10.1016/j.ahj.2013.07.011 |
work_keys_str_mv | AT berrycolin fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT laylandjamie fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT soodarvind fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT curzennickp fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT balachandrankanarathp fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT dasraj fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT junejoshahid fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT hendersonroberta fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT briggsandrewh fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT fordian fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial AT oldroydkeithg fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial |